The Indian CDMO Piramal Pharma Solutions has announced its intention to invest $80 million to expand its Lexington, Kentucky facility, which specialises in sterile compounding, liquid filling and lyophillization for sterile injectable pharmaceuticals.

The investment intends to enhance the site’s existing capacity and capabilities to enhance Piramal’s biologic manufacturing position and includes an additional 24 thousand square feet of manufacturing space; a new laboratory; and new machinery. Current peak capacity at the site is 104 product batches per annum, with this to increase to over 240 batches per annum upon completion of the expansion in Q1 2027.